Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center Identifier:
First received: December 1, 2010
Last updated: May 31, 2016
Last verified: May 2016

December 1, 2010
May 31, 2016
January 2011
December 2016   (final data collection date for primary outcome measure)
  • Safety as measured by the number of participants with adverse events. [ Time Frame: The phase I component is expected to be complete within 3 months. ] [ Designated as safety issue: Yes ]
  • Time to Progression (phase II)as measured by abdominal magnetic resonance imaging. [ Time Frame: The phase II component is expected to be complete within 2 years. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01264705 on Archive Site
Overall Survival. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC). This study will be activated at the UT Southwestern Medical Center, comprised of The Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Hospitals-St. Paul and Parkland Memorial Hospital System. Advanced HCC is defined as disease that is not amenable to surgical resection or orthotopic liver transplantation or is metastatic in nature.
The investigators are looking for men or women aged 18 years or older with hepatocellular carcinoma not suitable for surgical resection or hepatic transplantation. Prior locoregional therapy including but not limited to transarterial chemoembolization (TACE), radiofrequency ablation (RFA) or ethanol injection is allowed as long as the treatment was 4 weeks previous. Patients must be Child-Pugh A with no previous treatment with sorafenib or other vascular endothelial growth factor (VEGF) inhibitors.
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hepatocellular Carcinoma
  • Liver Cancer
Drug: bavituximab and sorafenib
Bavituximab:0.3,1.0,and 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
Experimental: Bavituximab and Sorafenib
Intervention: Drug: bavituximab and sorafenib
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
December 2016
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:

    • Histologically confirmed.
    • MRI or CT consistent with liver cirrhosis and at least one solid liver lesion >2 cm with early enhancement and delayed enhancement washout regardless of AFP.
    • AFP >400 ng/ml and evidence of at least one solid liver lesion >2 cm regardless of specific imaging characteristics on CT or MRI.
  2. Locally advanced or metastatic disease.
  3. Patients with locally advanced disease must have disease deemed to be unresectable or not eligible for hepatic transplantation. Determination will occur in the weekly GI DMT meeting by surgical oncologists and transplant surgeons.
  4. Measurable disease, as defined as lesions that can accurately be measured in at least one dimension (longest diameter to be measured) according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at least 2 cm with conventional techniques or at least 1 cm with spiral computed tomography.
  5. Child-Pugh Score A.
  6. Age ≥ 18 years.
  7. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.
  8. Absolute neutrophil count ≥ 1,500 cells/mm3.
  9. Platelet count ≥ 75,000 cells/mm3.
  10. Total bilirubin ≤ 3.0 mg/dl.
  11. Hemoglobin ≥ 8.5 g/dl.
  12. AST and ALT ≤ 5.0 times upper limit of normal.
  13. D-dimer ≤ 3 times upper limit of normal.
  14. INR ≤ 1.8 (therapeutic anticoagulation allowed as long as medically indicated.

Exclusion Criteria:

  1. History of bleeding diathesis or coagulopathy.
  2. Symptomatic or clinically active brain metastases.
  3. Major surgery within previous 4 weeks.
  4. History of thromboembolic events (including both pulmonary embolisms and deep vein thrombosis); central venous catheter-related thrombosis > 6 months prior is allowed.
  5. Prior adjuvant therapy with sorafenib or other Raf/MEK/RAS or VEGFR inhibitors. Prior adjuvant therapy is allowed provided it was completed > 6 months ago and there is documented recurrence of hepatocellular carcinoma.
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
STU 062010-150
Not Provided
Not Provided
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Not Provided
Principal Investigator: Adam C Yopp, MD UT Southwestern Medical Center
University of Texas Southwestern Medical Center
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP